Bispecific antibodies for selective immune regulation and for selective immune cell binding
AssigneeThe General Hospital Corporation
InventorsJohnson T. Wong, Robert B. Colvin
Life of this patent
Estimating the term…
Abstract
Bispecific antibodies can be used to alter the ratio and proliferation of T cell subsets, to selectively target cells that coexpress two different surface antigens such as the activated T cell subsets, or to block the cytolytic function of specific T cell subsets.
Claims34
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD3 and a second FAB portion specific for the interleukin-2 receptor, CD28, CD45 or CDTfr.
A method of detecting HIV viral proteins in peripheral blood mononuclear cells or whole blood wherein a bispecific CD3/CD8 monoclonal antibody is first added in vitro to said peripheral blood mononuclear cells or said whole blood rapidly induce HIV viral expression.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD3 and a second FAB portion specific for the interleukin-2 receptor.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD4 and a second FAB portion specific for the interleukin-2 receptor.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD8 and a second FAB portion specific for the interleukin-2 receptor.
An in vitro method of decreasing the ration of mammalian TX cells/mammalian TY cells in a mixture of cells, where said TX cells and said TY cells each bear CD3 antigen and said TX cells also bear a second mammalian T cell surface antigen, CD4, not present on said TY cells, said method comprising contacting said mixture with a CD3/CD4 bispecific antibody.
An in vivo method of decreasing the ratio of TX cells/TY cells in a mammal, where said TX cells and said TY cells each bear CD3 antigen and said TX cells also bear a second mammalian T cell surface antigen, CD4, not present on said TY cells, said method comprising administering to said mammal a CD3/CD4 bispecific antibody.
A method for selectively proliferating CD8 T-cells in a patient comprising administering to said patient a CD3/CD4 bispecific monoclonal antibody.
A method for selectively depleting CD4 T-cells in a patient comprising administering to said patient a CD3/CD4 bispecific monoclonal antibody.
An in vitro method for selectively proliferating CD8 T-cells in a mixture of cells containing T-cells, said method comprising incubating said mixture of cells with a CD3/CD4 bispecific monoclonal antibody.
An in vitro method for selectively depleting CD4 T-cells in a mixture of cells containing T-cells, said method comprising incubating said mixture of cells with a CD3/CD4 bispecific monoclonal antibody.
An in vitro method of decreasing the ratio of mammalian TX cells/mammalian TY cells in a mixture of cells, where said TX cells and said TY cells each bear CD3 antigen and said TX cells also bear a second mammalian T cell surface antigen, CD8, not present on said TY cells, said method comprising contacting said mixture with a CD3/CD8 bispecific antibody.
An in vivo method of decreasing the ratio of TX cells/TY cells in a mammal, where said TX cells and said TY cells each bear CD3 antigen and said TX cells also bear a second mammalian T cell surface antigen, CD8, not present on said TY cells, said method comprising administering to said mammal a CD3/CD8 bispecific antibody.
A method for selectively proliferating CD4 T-cells in a patient comprising administering to said patient a CD3/CD8 bispecific monoclonal antibody.
A method for selectively depleting CD8 T-cells in a patient comprising administering to said patient a CD3/CD8 bispecific monoclonal antibody.
An in vitro method for selectively proliferating CD4-bearing T-cells in a mixture of cells containing T-cells, said method comprising incubating said mixture of cells with a CD3/CD8 bispecific monoclonal antibody.
An in vitro method for selectively depleting CD8 T-cells in a mixture of cells containing T-cells, said method comprising incubating said biological sample with a CD3/CD8 bispecific monoclonal antibody.
A method for selectively targeting T-cells bearing both antigens recognized by a bispecific monoclonal antibody comprising contacting a mixture of cells containing T-cells with a bispecific monoclonal antibody selecting from the group consisting of:
- CD3/CD8;
- CD3/CD4;
- CD3/CD28;
- CD4/interleukin-2 receptor;
- CD8/interleukin-2 receptor;
- and CD8/CDTfr.
An in vitro method for detecting HIV in a population of cells comprising T cells, said method comprising first incubating said population of cells in vitro with CD3/CD8 and then measuring the level of an HIV protein.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD8 and a second FAB portion specific for Transferrin receptor.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD4 and a second FAB portion specific for Transferrin receptor.
A bispecific monoclonal antibody having a common Fc portion, a first FAB portion specific for CD3 and a second FAB portion specific for the interleukin-2 receptor.
Dependencies are inferred from the claim text.